Plain-English translation of NCT06647940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing orelabrutinib combined with a standard chemotherapy regimen (called R-CHOP) in patients with a specific type of aggressive blood cancer called CD5-positive diffuse large B-cell lymphoma. The study wants to see if adding this medication to the standard treatment improves how well patients respond and how long they stay cancer-free. If the treatment works well, patients may continue taking the medication on its own for a period of time after completing the initial treatment cycles.
Many patients with this type of blood cancer don't respond well enough to standard chemotherapy alone, and some relapse after treatment. This medication targets a specific protein involved in cancer cell growth, so researchers believe combining it with standard chemotherapy might help more patients achieve complete remission and stay in remission longer.
You likely qualify if…
You likely don't qualify if…
You would receive 8 cycles of treatment over about 6 months, with each cycle lasting 3 weeks. During this time, you would come to the hospital or clinic for chemotherapy infusions and to receive the new medication (as a pill you take at home). After completing these 8 cycles, if your cancer goes into complete remission, you would continue taking the medication alone for maintenance therapy. Throughout the trial, you would have regular blood tests, imaging scans, and check-ups to monitor how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China